The Protocol Specific Research Support (PSRS) provides funding for innovative, short term, feasibility and phase I clinical trials originating from scientific investigators within KCI. The primary objective is to foster investigator-initiated trials that bring new results from the basic science laboratories to KCI's clinics. PSRS provides funding to encourage expansion of the number of investigator-initiated protocols and the development of innovative trials that may have insufficient preliminary data to be competifive for peer reviewed funding. The Clinical Research Coordinator (CRC) and Business Analyst funded by PSRS provide data management and study coordination in support of high priority, innovative, feasibility and phase I invesfigator-inifiated clinical research protocols. The services provided by the CRC are in accordance with the services of the Clinical Trials Office Core (Secfion 9.1.10). The Business Analyst creates protocol specific calendars and electronic case report forms (eCRFs) within OnCore?. The information captured in the eCRF is used by the Biostatistics Core for protocol data analysis.
The purpose of PSRS is to provide data management support for innovafive, short term, feasibility and phase I clinical trials originating from scientific invesfigators within KCI. The primary objecfive is to foster investigator-initiated trials that bring new results from the basic science laboratories to the KCI clinics.
|Bao, Xun; Wu, Jianmei; Sanai, Nader et al. (2018) A liquid chromatography with tandem mass spectrometry method for quantitating total and unbound ceritinib in patient plasma and brain tumor. J Pharm Anal 8:20-26|
|Matherly, Larry H; Hou, Zhanjun; Gangjee, Aleem (2018) The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer. Cancer Chemother Pharmacol 81:1-15|
|Pollack, Murray M; Holubkov, Richard; Reeder, Ron et al. (2018) PICU Length of Stay: Factors Associated With Bed Utilization and Development of a Benchmarking Model. Pediatr Crit Care Med 19:196-203|
|Ali, Arif N; Zhang, Peixin; Yung, W K Alfred et al. (2018) NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol 137:39-47|
|Heath, Elisabeth I; Lynce, Filipa; Xiu, Joanne et al. (2018) Racial Disparities in the Molecular Landscape of Cancer. Anticancer Res 38:2235-2240|
|McFall, Thomas; McKnight, Brooke; Rosati, Rayna et al. (2018) Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen. J Biol Chem 293:1163-1177|
|McKnight, Brooke N; Viola-Villegas, Nerissa T (2018) Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging. Breast Cancer Res 20:130|
|Greenwald, Mark K; Ruterbusch, Julie J; Beebe-Dimmer, Jennifer L et al. (2018) Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population. Cancer :|
|Dyson, Greg; Farran, Batoul; Bolton, Susan et al. (2018) The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer. Am J Cancer Res 8:2088-2095|
|Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963|
Showing the most recent 10 out of 826 publications